NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Zevra Therapeutics, Inc. (ZVRA) Stock Analysis

Zevra Therapeutics, Inc. (ZVRA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ZVRA

$12.40

−$0.14 (−1.12%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ZVRA with… →

ZVRA Key Statistics

As of Sep 4, 2026
Trading
Open
$12.44
Previous Close
$12.54
Day's Range
12.20–12.65
52-Week Range
7.16–15.04
Volume
1.03M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.95
Valuation
Market Cap
$736.36M
P/E Ratio
13.33
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
11.52
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
10.67
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.41
EPS (ttm)Profit attributable to each share over the last twelve months.
0.93
Financials (FY)
Revenue (FY)
$106.47M+350.91%
Net Income (FY)
$83.23M
Profit marginThe share of revenue left as profit after all costs and taxes.
42.82%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
59.38M
1-Year Return
+38.86%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
1.45M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ZVRA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+38.39%
2025+7.43%
2024+27.33%
2023+42.70%
2022−47.30%
2021−22.23%
2020+84.70%
2019−78.71%
2018−56.05%
2017+37.29%
2016 (partial year)−28.74%

As of September 4, 2026.

ZVRA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$106.47M$83.23M78.2%
2024$23.61M−$105.51M−446.9%
2023$27.46M−$46.05M−167.7%
2022$10.16M−$26.77M−263.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$106.47M$89.99M−$4.23M$83.23M78.2%
2024$23.61M$16.20M−$87.00M−$105.51M−446.9%
2023$27.46M$25.29M−$49.60M−$46.05M−167.7%
2022$10.16M$9.94M−$24.90M−$26.77M−263.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ZVRA Valuation vs Biotechnology Median

Median of 656 stocks
MetricZVRABiotechnology medianvs median
P/E13.3312.576% above
P/S ratio5.4115.2665% below
Profit margin42.82%0.00%42.8 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Zevra Therapeutics, Inc. (ZVRA) at $736.36M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 61.

The most recent close on file for ZVRA is $12.40, dated September 4, 2026. That is −$0.14 (−1.12%) against the previous close. Over the past 52 weeks the price has ranged from $7.16 to $15.04. The latest close sits 73.18% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $106.47M. That is +350.91% against the prior fiscal year, when revenue was $23.61M. Net income for the same year was $83.23M. Profit margin runs at 42.82%. That is 42.8 percentage points above the Biotechnology median of 0%. Earnings per share on a trailing basis come to 0.93.

Across the 4 fiscal years on file, revenue moves from $10.16M in 2022 to $106.47M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 13.33. That is 6.05% above the Biotechnology median of 12.57. The forward P/E on file is 11.52. The PEG ratio, which sets the P/E against expected earnings growth, reads 10.67. The price-to-sales ratio is 5.41. On price-to-sales that is 64.55% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.95. Daily returns over the trailing 10 years annualize to a volatility of 82.7%. The trailing one-year price return is +38.86%. Across 10 years the annualized return works out at −16.39%.

Growth & Income

The record shows no dividend for ZVRA.

Across the complete calendar years on file, 2020 returned +84.70% and 2019 returned −78.71%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the price is +38.39%.

Peer Comparison

Zevra Therapeutics, Inc. (ZVRA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Zevra Therapeutics, Inc. ZVRA $736.36M 13.3
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Zevra Therapeutics, Inc. trades at a P/E of 13.3.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Visit website →